Opinions+ - STAT

First Opinion By Cecile Riboud

In biopharma mergers and acquisitions, managing regulatory compliance early protects return on investment

Opinions+ By Christopher Leo, Christian Thienel, and Brendan Wang

Early price setting, other market access planning is key for early-stage drug, device companies

Opinions+ By Nick Stephens

How to create successful leadership teams for cell and gene therapy companies

Opinions+ By Grey Wilkinson

Biomarkers provide a bridge to the next frontier in immuno-oncology

Opinions+ By Christopher Boone and Viraj Narayanan

How to apply real-world evidence to outsmart cancer

Opinions+ By Leslie Loveless

To recruit top life sciences executives, companies need solid strategies in 2019

Opinions+ By Vijay Ramakrishnan and Edwin P. Ching

Inappropriate ‘interchangeability’ requirement for biosimilars will cost the U.S. billions

Opinions+ By Elizabeth Cooney

Public distrust is high, PBMs are the problem, but the future is bright: a survey of biopharma pros

Opinions+ By Jeremy Schafer

Rare diseases are losing their immunity in formulary exclusion lists

Opinions+ By Elizabeth Cooney

Tell us what you really think: A survey on drug prices, biotech, and Alex Azar

Opinions+ By STAT staff

From the C-suite: Biopharma execs teach students a lesson

Opinions+ By STAT staff

From the C-Suite: nurturing diversity in the workplace

Opinions+ By Elizabeth Cooney

Industry insiders are upbeat about 2018, but that doesn’t mean more hiring

Opinions+ By STAT staff

From the C-Suite: advice on dealing with antsy investors

Opinions+ By STAT staff

From the C-Suite: How to coach a team to respond to setbacks

Opinions+ By STAT staff

From the C-Suite: How to learn leadership skills from mentors as diverse as Gen. Patton — and mom

Opinions+ By STAT staff

From the C-Suite: How to build a strong workplace culture

Opinions+ By Robert M. Thomas Jr.

Most Read

Why medtech is a different beast than biotech in the life sciences pack

Microbiome drug development: a rapidly evolving field

A 1962 law slowed drug development. Changing it could slash drug prices

From the C-Suite: Biopharma execs open up on what tests them as leaders

From the C-Suite: Biotech execs share their best interview questions — and the answers they want to hear

Building the perfect wearable for clinical trials

Three steps toward creating a functioning U.S. biosimilars market

Unprecedented development of Covid-19 vaccines, treatments points to biopharma’s future

All Coverage

In biopharma mergers and acquisitions, managing regulatory compliance early protects return on investment

Early price setting, other market access planning is key for early-stage drug, device companies

How to create successful leadership teams for cell and gene therapy companies

Biomarkers provide a bridge to the next frontier in immuno-oncology

How to apply real-world evidence to outsmart cancer

To recruit top life sciences executives, companies need solid strategies in 2019

Inappropriate ‘interchangeability’ requirement for biosimilars will cost the U.S. billions

Public distrust is high, PBMs are the problem, but the future is bright: a survey of biopharma pros

Rare diseases are losing their immunity in formulary exclusion lists

Tell us what you really think: A survey on drug prices, biotech, and Alex Azar

From the C-suite: Biopharma execs teach students a lesson

From the C-Suite: nurturing diversity in the workplace

Industry insiders are upbeat about 2018, but that doesn’t mean more hiring

From the C-Suite: advice on dealing with antsy investors

From the C-Suite: How to coach a team to respond to setbacks

From the C-Suite: How to learn leadership skills from mentors as diverse as Gen. Patton — and mom

From the C-Suite: How to build a strong workplace culture

Doctors, beware: Prosecutors are zooming in on health care fraud as opioid crisis mounts